NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

H3N2 M2SR in Pediatric Population

Phase 1

Completed

Conditions: Influenza
Influenza Immunisation

Interventions: Biological: Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine
Other: Placebo
Biological: Quadrivalent MDCK Inactivated Influenza Vaccine

First Posted Date: 2018-06-12

Last Posted Date: 2021-10-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 43

Registration Number: NCT03553940

Locations: 🇺🇸
Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States

Safety and Efficacy of FMT in Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD)

Phase 1

Terminated

Conditions: Probiotic Therapy
Clostridial Infection
Dysbiosis

Interventions: Procedure: Fecal Microbiota Transplantation (FMT)
Drug: Saline

First Posted Date: 2018-06-06

Last Posted Date: 2022-05-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT03548051

Locations: 🇺🇸
Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States
🇺🇸
Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States
🇺🇸
Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States

A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area

Phase 1

Terminated

Conditions: Immunisation
Gastroenteritis Escherichia Coli

Interventions: Other: Placebo
Biological: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine

First Posted Date: 2018-06-06

Last Posted Date: 2023-08-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 75

Registration Number: NCT03548064

Locations: 🇧🇩
International Center for Diarrheal Disease Research Bangladesh - Infectious Diseases Division - Mucosal Immunology and Vaccinology Unit, Dhaka, Bangladesh

Follow up of LEAP Participants and Their Families

Completed

Conditions: Peanut Allergy

First Posted Date: 2018-06-06

Last Posted Date: 2024-03-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1868

Registration Number: NCT03546413

Locations: 🇬🇧
Evelina London Children's Hospital, London, United Kingdom

Cockroach Immunotherapy in Children and Adolescents

Phase 2

Completed

Conditions: Persistent Asthma

Interventions: Biological: Placebo for German cockroach allergenic extract
Biological: German cockroach allergenic extract

First Posted Date: 2018-05-30

Last Posted Date: 2023-05-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 82

Registration Number: NCT03541187

Locations: 🇺🇸
St. Louis Children's Hospital: Allergy, Immunology and Pulmonary Medicine Program, Saint Louis, Missouri, United States
🇺🇸
University of Texas Southwestern Medical School, Dallas, Texas, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

and more 8 locations

Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults

Phase 2

Completed

Conditions: Pertussis
Pertussis Immunisation

Interventions: Biological: BPZE1
Other: Placebo

First Posted Date: 2018-05-30

Last Posted Date: 2022-02-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 50

Registration Number: NCT03541499

Locations: 🇺🇸
Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center, Nashville, Tennessee, United States

Sample Collection From Healthy Volunteers for Assay Optimization

Recruiting

Conditions: Healthy Volunteers

First Posted Date: 2018-05-29

Last Posted Date: 2024-12-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 600

Registration Number: NCT03538600

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

Phase 1

Completed

Conditions: HIV Antibodies

Interventions: Biological: VRC-HIVMAB091-00-AB
Biological: rHuPH20

First Posted Date: 2018-05-29

Last Posted Date: 2024-02-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 33

Registration Number: NCT03538626

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children

Completed

Conditions: Dengue Fever

First Posted Date: 2018-05-23

Last Posted Date: 2024-12-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 775

Registration Number: NCT03534245

Locations: 🇰🇭
Kampong Speu Referral Hospital, Chbar Mon, Kampong Speu, Cambodia

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

Phase 2

Active, not recruiting

Conditions: Idiopathic CD4 T Cell Lymphocytopenia

Interventions: Biological: Gardasil 9

First Posted Date: 2018-05-09

Last Posted Date: 2024-12-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 54

Registration Number: NCT03519464

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy